



Resverlogix Appoints Dicky To to its Board of Directors

CALGARY, Alberta, Dec. 20, 2019 -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that Mr. Dicky To has been appointed to the Company's Board of Directors. His appointment is effective as of December 19, 2019.

Dicky is a partner of ORI Capital and has over 25 years of experience in structure, transaction and tax advisory. Before joining ORI Capital, he was a partner of RSM Hong Kong and worked with the Hong Kong and Shanghai offices of Arthur Andersen for 10 years.

[As previously announced](#), in connection with the convertible debenture issued by the Company on September 26, 2019, ORI Capital was entitled to nominate a director to the Company's Board of Directors.

"On behalf of Resverlogix, we are pleased to have Dicky join the Board of Directors and look forward to his many contributions," said Donald McCaffrey, President and CEO of the Company.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on:

- Twitter: [@Resverlogix_RVX](#)
- LinkedIn: <https://www.linkedin.com/company/resverlogix-corp/>

For further information please contact:

Investor Relations

Email: ir@resverlogix.com

Phone: 403-254-9252

Or visit our website: www.resverlogix.com

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone in the treatment of high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.